Lyra Therapeutics, Inc. (LYRA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1234270,
    "name": "Lyra Therapeutics, Inc.",
    "stock_name": "Lyra Therapeutics, Inc.",
    "full_name": "Lyra Therapeutics, Inc.",
    "name_url": "stocks-analysis/lyra-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "4.50",
    "chg": 0.49,
    "chgp": "12.22%",
    "dir": 1,
    "prev_price": "4.01",
    "mcapval": "10.85",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US55234L1052",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "93.38 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/lyra-therapeutics-inc-1234270-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Lyra Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-lyra-therapeutics-inc-technically-bullish-or-bearish-3547268",
        "imagepath": "",
        "date": "2025-09-20 19:51:21",
        "description": "As of 20 August 2025, the technical trend for Lyra Therapeutics, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish daily moving average and a bearish monthly Bollinger Band. The weekly MACD remains mildly bullish, but the overall indicators suggest weakness, particularly with the KST and OBV showing mixed signals. The stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -38.47% compared to the S&P 500's 12.22%...."
      },
      {
        "title": "Is Lyra Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-lyra-therapeutics-inc-overvalued-or-undervalued-3543679",
        "imagepath": "",
        "date": "2025-09-20 18:25:41",
        "description": "As of 12 August 2025, the valuation grade for Lyra Therapeutics, Inc. changed from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its high Price to Book Value of 8.31 and negative EV to EBIT and EV to EBITDA ratios of -0.10, suggesting that it is not generating positive earnings or cash flow. Additionally, the Return on Equity (ROE) is alarmingly low at -1111.31%, further underscoring the company's struggles.\n\nIn comparison to its peers, Lyra Therapeutics, Inc. shows stark contrasts; for instance, 2seventy Bio, Inc. has a P/E ratio of 76.93, while Scilex Holding Co. and Generation Bio Co. also reflect negative valuations. The company's stock performance has been dismal, with a year-to-date return of -38.47% compared to the S&P 500's gain of 12.22%, and a staggering -98.94% return over the past five years against the S&P 500's 96.6..."
      }
    ],
    "total": 7,
    "sid": "1234270",
    "stock_news_url": "https://www.marketsmojo.com/news/lyra-therapeutics-inc-1234270"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Lyra Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:51:21

As of 20 August 2025, the technical trend for Lyra Therapeutics, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish daily moving average and a bearish monthly Bollinger Band. The weekly MACD remains mildly bullish, but the overall indicators suggest weakness, particularly with the KST and OBV showing mixed signals. The stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -38.47% compared to the S&P 500's 12.22%....

Is Lyra Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:25:41

As of 12 August 2025, the valuation grade for Lyra Therapeutics, Inc. changed from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its high Price to Book Value of 8.31 and negative EV to EBIT and EV to EBITDA ratios of -0.10, suggesting that it is not generating positive earnings or cash flow. Additionally, the Return on Equity (ROE) is alarmingly low at -1111.31%, further underscoring the company's struggles. In comparison to its peers, Lyra Therapeutics, Inc. shows stark contrasts; for instance, 2seventy Bio, Inc. has a P/E ratio of 76.93, while Scilex Holding Co. and Generation Bio Co. also reflect negative valuations. The company's stock performance has been dismal, with a year-to-date return of -38.47% compared to the S&P 500's gain of 12.22%, and a staggering -98.94% return over the past five years against the S&P 500's 96.6...

View All News